Dr Rafael Fonesca reviews data from the TriMM-2 study presented at ASCO 2023 investigating combination talquetamab plus daratumumab for patients with relapsed/refractory multiple myeloma, highlighting a 78% response rate to talquetamab, but noting side effects like CRS and infections....
This study was funded by Janssen Research & Development, LLC. Medical writing support was provided by Craig Turner, MSc, of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC. 展开 关键词: MM relapsed/refractory multiple myeloma bispecifics multiple myeloma ...
TRIMM-2 Study Shows Efficacy in R/R Multiple Myelomadoi:10.1097/01.COT.0001095668.90597.eaDibash Kumar DasWolters Kluwer Health, Inc.Oncology Times
#song. You may only use this file for private study, scholarship, or research. # #---# SONG: Trimm trabb GROUP: blur ALBUM: 13 TABBED BY: Diego López (diegolopez@altavista.net) This is my first tab, so, if you see anything wrong here, send me an email to: diegolopez@altavista....